Switch theme
Sign up to access all valuation multiples
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
2014
534
LTM Revenue $2.4M
LTM EBITDA -$807M
$5.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Revolution Medicines has a last 12-month revenue (LTM) of $2.4M and a last 12-month EBITDA of -$807M.
In the most recent fiscal year, Revolution Medicines achieved revenue of n/a and an EBITDA of -$678M.
Revolution Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Revolution Medicines valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$807M | XXX | -$678M | XXX | XXX | XXX |
| EBITDA Margin | -34181% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$809M | XXX | -$690M | XXX | XXX | XXX |
| EBIT Margin | -34269% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$720M | XXX | -$600M | XXX | XXX | XXX |
| Net Margin | -30500% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Revolution Medicines's stock price is $39.
Revolution Medicines has current market cap of $7.3B, and EV of $5.4B.
See Revolution Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.4B | $7.3B | XXX | XXX | XXX | XXX | $-4.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Revolution Medicines has market cap of $7.3B and EV of $5.4B.
Revolution Medicines's trades at 463.8x EV/Revenue multiple, and -7.9x EV/EBITDA.
Equity research analysts estimate Revolution Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Revolution Medicines has a P/E ratio of -10.2x.
See valuation multiples for Revolution Medicines and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.3B | XXX | $7.3B | XXX | XXX | XXX |
| EV (current) | $5.4B | XXX | $5.4B | XXX | XXX | XXX |
| EV/Revenue | 2274.2x | XXX | 463.8x | XXX | XXX | XXX |
| EV/EBITDA | -6.7x | XXX | -7.9x | XXX | XXX | XXX |
| EV/EBIT | -6.6x | XXX | -7.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2274.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.2x | XXX | -12.2x | XXX | XXX | XXX |
| EV/FCF | -7.5x | XXX | -9.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRevolution Medicines's last 12 month revenue growth is 244%
Revolution Medicines's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Revolution Medicines's rule of 40 is -3471% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Revolution Medicines's rule of X is -33570% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Revolution Medicines and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 244% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -34181% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3471% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -33570% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Revolution Medicines acquired XXX companies to date.
Last acquisition by Revolution Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . Revolution Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Revolution Medicines founded? | Revolution Medicines was founded in 2014. |
| Where is Revolution Medicines headquartered? | Revolution Medicines is headquartered in United States of America. |
| How many employees does Revolution Medicines have? | As of today, Revolution Medicines has 534 employees. |
| Who is the CEO of Revolution Medicines? | Revolution Medicines's CEO is Dr. Mark A. Goldsmith, M.D., PhD. |
| Is Revolution Medicines publicy listed? | Yes, Revolution Medicines is a public company listed on NAS. |
| What is the stock symbol of Revolution Medicines? | Revolution Medicines trades under RVMD ticker. |
| When did Revolution Medicines go public? | Revolution Medicines went public in 2020. |
| Who are competitors of Revolution Medicines? | Similar companies to Revolution Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Revolution Medicines? | Revolution Medicines's current market cap is $7.3B |
| What is the current revenue of Revolution Medicines? | Revolution Medicines's last 12 months revenue is $2.4M. |
| What is the current revenue growth of Revolution Medicines? | Revolution Medicines revenue growth (NTM/LTM) is 244%. |
| What is the current EV/Revenue multiple of Revolution Medicines? | Current revenue multiple of Revolution Medicines is 2274.2x. |
| Is Revolution Medicines profitable? | Yes, Revolution Medicines is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Revolution Medicines? | Revolution Medicines's last 12 months EBITDA is -$807M. |
| What is Revolution Medicines's EBITDA margin? | Revolution Medicines's last 12 months EBITDA margin is -34181%. |
| What is the current EV/EBITDA multiple of Revolution Medicines? | Current EBITDA multiple of Revolution Medicines is -6.7x. |
| What is the current FCF of Revolution Medicines? | Revolution Medicines's last 12 months FCF is -$717M. |
| What is Revolution Medicines's FCF margin? | Revolution Medicines's last 12 months FCF margin is -30377%. |
| What is the current EV/FCF multiple of Revolution Medicines? | Current FCF multiple of Revolution Medicines is -7.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
